India is presently the fourth largest medical device market in Asia, boasting an industry valued at USD 14 billion and exports totaling USD 3.7 billion. The MedTech program is expected to assist local manufacturers in expanding the market value to...
The Indian pharmaceutical market (IPM) experienced a 6.1 percent value increase in October 2024, with significant therapies demonstrating favorable value growth, as per a report from market research firm Pharmarack. Among these areas, the cardiac...
SystImmune, Inc (SystImmune), a biotechnology company in the clinical stage, declared that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC)...
Moderna, Inc., a pioneer in mRNA medicine development, revealed that Health Canada has authorized mRESVIA (mRNA vaccine for Respiratory Syncytial Virus) for active immunization aimed at preventing lower respiratory tract infections caused by...
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company fully owned and autonomously operating as a subsidiary of Bayer AG, announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug...
Bayer revealed that it received approval from the U.S. Food and Drug Administration (FDA) for its MEDRAD® Centargo CT Injection System, a groundbreaking multi-patient injector that enhances workflow efficiency through design elements that align...
The US FDA awards Rare Paediatric Disease Designation to encourage the development of drugs for serious conditions impacting fewer than 200,000 children in the US. Since these illnesses present distinct hurdles for drug development...
The European Medicines Agency has authorized Dupixent (dupilumab) for the treatment of eosinophilic esophagitis (EoE) in children starting from one year old. The approval specifically pertains to children between the ages of one and 11 years who...
In October 2024, the pharmaceutical sector disclosed 102 transactions worth $8.9 billion, representing a 69 percent decrease in deal value relative to October 2023. GlobalData reports that this deal activity also did not meet the average from the...
CytoDyn Inc., a biotech firm working on leronlimab, a CCR5 inhibitor with possible therapeutic uses, revealed that it has obtained approval from the US FDA to begin its phase II cancer trial. The research will assess how effective leronlimab is...
, CDSCO.jpg)
